MacroGenics宣布MGC030（ADC）I期临床完成首例患者给药，靶点尚未披露

Nasdaq ends higher in big rebound as bond rally offsets tech softness, hot PPI
ROCKVILLE, Md. - MacroGenics Inc. (NASDAQ:MGNX) announced today that the first patient has been dosed in a Phase 1 study of MGC030, an antibody-drug conjugate targeting an undisclosed antigen, for patients with advanced solid tumors.
The open-label, multi-center study will evaluate the safety, tolerability, pharmacokinetics, immunogenicity and preliminary antitumor activity of MGC030, according to a press release statement. The trial will enroll participants with relapsed or refractory solid tumors that are unresectable, locally advanced or metastatic, including urothelial, colorectal, gastric, gastroesophageal junction, esophageal and pancreatic cancers.
The dose escalation portion will enroll up to 54 participants, with potential for further expansion at selected dose levels.
MGC030 incorporates Synaffix’s ADC technology and the SYNtecan E topoisomerase I inhibitor-based linker-payload, which consists of a cleavable, exatecan-based cytotoxic payload conjugated at a drug-to-antibody ratio of 4. The company stated there are currently no approved therapeutics directed against this target.
"The dosing of a first patient with MGC030 builds upon the strong early-stage clinical momentum we have sustained across our innovative ADC pipeline, as this molecule is now our third ADC in active clinical development," said Ezio Bonvini, Senior Vice President and Chief Scientific Officer of MacroGenics.
The clinical trial information is available at clinicaltrials.gov under identifier NCT07822399.
MacroGenics is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for cancer treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.